Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer

<p>Patient characteristics.</p>

Сохранить в:

Библиографические подробности
Главный автор:	Bunpei Isoda (22273897) (author)
Другие авторы:	Masanobu Shiga (22273900) (author), Shuya Kandori (20806494) (author), Shota Takahashi (22273903) (author), Akifumi Omiya (22273906) (author), Tomoki Ishida (22273909) (author), Kotoe Matsuda (22273912) (author), Hiromichi Sakurai (22273915) (author), Bryan J. Mathis (20803922) (author), Ken Tanaka (22273918) (author), Manabu Komine (22273921) (author), Masahiro Iinuma (22273924) (author), Akira Joraku (22273927) (author), Hiromitsu Negoro (17411086) (author), Masakazu Tsutsumi (22273930) (author), Takamitsu Inoue (22273933) (author), Jun Miyazaki (22273936) (author), Hiroyuki Nishiyama (18287202) (author)
Опубликовано:	2025
Предметы:	Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Cell Signaling Clinical-stage Research Genitourinary Cancers Renal cancer Immunotherapy Toxicities/irAEs Immune Cells And The Microenvironment Protein Tyrosine Kinases Tumor Microenvironment
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы